Seres Therapeutics

Seres Therapeutics is a microbiome therapeutics company headquartered in Cambridge, Massachusetts and was founded in 2010 by Noubar Afeyan and David Berry. Seres Therapeutics is using a discovery and design platform for developing new therapies using live bacteria for the treatment of diseases that are a result of microbiome deficiencies. Seres Therapeutics is focused on developing therapies for the treatment of Clostridium difficile infection (CDI), inflammatory bowel disease, and an oral microbiome therapy for improving the safety and efficacy of immunotherapies.

On November 27, 2012 Seres Therapeutics closed their series A funding round with an undisclosed amount of funding from Flagship Pioneering and Enso Ventures.

On may 23, 2014 Seres Therapeutics closed their series B funding round with$10 million in funding from Mayo Clinic, Flagship Pioneering, Enso ventures, and Alexandria Venture.

On December 2, 2014 Seres Therapeutics closed their series C funding round with $48 million in funding from Flagship Pioneering.

On January 6, 2015 Seres Therapeutics closed their series D funding round with $65 million in funding from Nestlé Health Science.